PetMed Express, Inc. Provides Update on Status of Fourth Quarter and FY 2025 Results
PetMed Express, Inc. (the “Company”) dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) has provided an important update concerning its fourth quarter and fiscal year 2025 results alongside its Form 10-K filing.
Details on Filing Challenges
Recently, the Company filed a Form 12b-25 to announce that it would not be able to submit its Form 10-K for the fiscal year ending March 31, 2025, within the required timeframe. This situation arose due to ongoing efforts to compile and verify necessary financial data and disclosures.
Challenges Faced
The Audit Committee received anonymous reports via its whistleblower hotline on several matters. These concerns include issues with revenue recognition related to certain autoship orders during the last fiscal quarter, which triggered some customer complaints. Additionally, the impact of a promotional $50 coupon on customer acquisition metrics was raised.
Investigation Underway
In response to these reports, the Audit Committee enlisted external legal counsel and advisors to conduct an investigation, which is currently in progress. As of now, PetMed Express does not anticipate that the findings from this investigation will materially affect its previously disclosed preliminary financial results for the quarter or the fiscal year ending March 31, 2025.
Company Overview
Founded in 1996, PetMeds stands out as a pioneer in the direct-to-consumer pet healthcare industry. This reputable national online pharmacy is licensed in all 50 states and has a team of expert pharmacists committed to promoting pet wellness. The Company boasts a wide range of health solutions under its PETS family of brands, including well-known pharmaceuticals, compounded medications, and high-quality OTC supplements and nutrition products aimed at enhancing pet health.
Commitment to Quality and Care
PetMeds and PetCareRx strive to empower pet owners by ensuring their dogs, cats, and even horses enjoy longer, healthier lives. With a focus on value, convenience, and exceptional care, they continue to be a trusted source for pet healthcare needs.
Looking Ahead
As PetMed Express works diligently to finalize its financial review, it remains committed to transparency and accountability. The Company aims to submit its 2025 Form 10-K as soon as circumstances allow.
Frequently Asked Questions
What challenges is PetMed Express facing regarding its Form 10-K filing?
The Company is unable to file its Form 10-K due to ongoing compilation and review of financial data, prompted by anonymous reports regarding revenue recognition and customer complaints.
What is the Audit Committee currently doing?
The Audit Committee is investigating concerns brought to their attention, which involves external legal counsel and other advisors as part of their due diligence.
Will the investigation affect previous financial results?
PetMed Express does not expect the outcome of the investigation to significantly impact its previously announced preliminary financial results.
How long is the investigation expected to last?
The duration of the ongoing investigation is currently uncertain, and no definite conclusions have been reached as of now.
Who can I contact for more investor information?
For inquiries regarding investor relations, you can contact ICR, LLC at (646) 277-1260 or via email at investor@petmeds.com.
